Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLN-619 in advanced solid tumors
NCT05117476Phase 1Active, not recruiting
- Sponsor
- Cullinan Therapeutics
- Start
- Oct 2021
- Primary completion
- Mar 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of cln-619 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), Cervical Cancer (CC) and 2 more (7 arms), sponsored by Cullinan Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 24 months, Best Overall Response and 5 more. Started Oct 2021; status: active, not recruiting.
02
Drugs
cln-619
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)Cervical Cancer (CC)endometrial cancer (EC)ovarian cancer
Beyond the preview
Go deeper on NCT05117476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05117476.